Study finds potential new target for Alzheimer's disease - glucose metabolism-related protein

Over the past few years, research on Alzheimer's has focused on amyloid proteins and tau proteins, which researchers believe are the cause of memory loss and other obvious symptomsThe results of a large-scale Alzheimer's-related protein study published in the journal Nature Medicine have found a new breakthrough in the discovery of potential therapeutic targetsThe study conducted a large-scale analysis of Alzheimer's-related proteomics, revealing changes in patients' protein networks and proposing new potential drug targetsthe study, led by a team at the Emory School of Medicine, collected brain tissue from 2,000 alzheimer's patients, as well as 400 samples of cerebrospinal fluid, and analyzed more than 3,000 protein expression patternsStudies have shown that glucose metabolite proteins are closely related to cognitive impairments associated with Alzheimer's diseaseProteins that protect cells in the brain that support cells (star-shaped glial cells and small glial cells) also play a key role in the pathology of Alzheimer's diseasethe study is based on a previous study by the National Institute on Aging (NIA), part of the National Institutes of Health (NIH), which found that abnormal glucose breakdown in the brain is associated with the formation of amyloid plaques and memory loss in the brainProteins that control glucose breakdown and convert into energy increase in the cerebrospinal fluid of Alzheimer's patientsIncreased levels of these proteins can also be seen in groups with signs of onset but have not yet shown obvious symptomsresearchers also observed that changes in proteins that control glucose metabolism cause anti-inflammatory reactions in glial cellsThey conclude that Alzheimer's actually begins with the brain's intention to protect nerve cellsThe glucose-related proteinfound in cerebrospinal fluid confirms this hypothesisDr Madhav Thambisetty, a researcher atNIA, said: "We have long been studying the possible link between abnormal glucose metabolism in the brain and changes associated with Alzheimer's diseaseRecent analysis suggests that these proteins may also have the potential to detect biomarkers as liquids, detecting the presence of disease setypes in the early stages of the diseaseDrSuzana Petanceska, program director of the NIA Alzheimer's New Target Discovery Program, said the data from the study "could be a rich source of new targets for the treatment and prevention of Alzheimer's disease." In recent years, nia has funded a series of projects using glucose metabolism research to find new treatments for Alzheimer's disease, including early research on t3D Therapeutics' drug T3D-959, which targets the regulation of metabolic abnormalities in glucose and fat in the brain In November, T3D raised $15 million in round B financing to help the drug enter clinical trials reference source: Alzheimer's researchers link glucose pedi to pathology, afounding new drug targets